368 related articles for article (PubMed ID: 28839466)
21. MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway.
Duan X; Li S; Holmes JA; Tu Z; Li Y; Cai D; Liu X; Li W; Yang C; Jiao B; Schaefer EA; Fusco DN; Salloum S; Chen L; Lin W; Chung RT
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321333
[TBL] [Abstract][Full Text] [Related]
22. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
[TBL] [Abstract][Full Text] [Related]
23. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
24. Proteomic Analysis of Nuclear Hepatitis B Virus Relaxed Circular DNA-Associated Proteins Identifies UV-Damaged DNA Binding Protein as a Host Factor Involved in Covalently Closed Circular DNA Formation.
Marchetti AL; Zhang H; Kim ES; Yu X; Jang S; Wang M; Guo H
J Virol; 2022 Jan; 96(2):e0136021. PubMed ID: 34705558
[TBL] [Abstract][Full Text] [Related]
25. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
26. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
28. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
Ramanan V; Shlomai A; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
Sci Rep; 2015 Jun; 5():10833. PubMed ID: 26035283
[TBL] [Abstract][Full Text] [Related]
29. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
30. Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis.
Zhao Q; Chang J; Rijnbrand R; Lam AM; Sofia MJ; Cuconati A; Guo JT
J Virol; 2022 Dec; 96(24):e0115022. PubMed ID: 36448800
[TBL] [Abstract][Full Text] [Related]
31. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
32. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.
Kitamura K; Que L; Shimadu M; Koura M; Ishihara Y; Wakae K; Nakamura T; Watashi K; Wakita T; Muramatsu M
PLoS Pathog; 2018 Jun; 14(6):e1007124. PubMed ID: 29928064
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.
Kato Y; Tabata H; Sato K; Nakamura M; Saito I; Nakanishi T
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638909
[TBL] [Abstract][Full Text] [Related]
34. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.
Yan Z; Zeng J; Yu Y; Xiang K; Hu H; Zhou X; Gu L; Wang L; Zhao J; Young JAT; Gao L
J Hepatol; 2017 Jun; 66(6):1149-1157. PubMed ID: 28213165
[TBL] [Abstract][Full Text] [Related]
35. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.
Zheng Q; Bai L; Zheng S; Liu M; Zhang J; Wang T; Xu Z; Chen Y; Li J; Duan Z
Mol Med Rep; 2017 Nov; 16(5):7199-7204. PubMed ID: 28944845
[TBL] [Abstract][Full Text] [Related]
36. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
37. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9.
Kostyushev D; Kostyusheva A; Brezgin S; Zarifyan D; Utkina A; Goptar I; Chulanov V
Sci Rep; 2019 Feb; 9(1):1847. PubMed ID: 30755668
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA/cas9 produces a synergistic antiviral effect in HBV infection.
Zhen S; Qiang R; Lu J; Tuo X; Yang X; Li X
Mol Immunol; 2021 Feb; 130():7-13. PubMed ID: 33340931
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B Virus-Encoded MicroRNA Controls Viral Replication.
Yang X; Li H; Sun H; Fan H; Hu Y; Liu M; Li X; Tang H
J Virol; 2017 May; 91(10):. PubMed ID: 28148795
[TBL] [Abstract][Full Text] [Related]
40. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
